News from immune pharmaceuticals inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Nov 26, 2014, 16:15 ET

Immune Pharmaceuticals Inc. Completes Underwriter's Exercise Of Partial Over-Allotment Option

 Immune Pharmaceuticals Inc. (NasdaqCM: IMNP; "Immune" or "the Company"), a clinical stage biopharmaceutical company that engages in the...

Nov 25, 2014, 16:15 ET

Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants

Immune Pharmaceuticals Inc. (NasdaqCM: IMNP; "Immune" or "the Company"), a clinical stage biopharmaceutical company that engages in the development...

Nov 20, 2014, 09:00 ET

Immune Pharmaceuticals Inc. Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company"), a clinical stage biopharmaceutical company that engages in the...

Nov 19, 2014, 16:15 ET

Immune Pharmaceuticals Inc. Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company"), a clinical stage biopharmaceutical company that engages in the...

Nov 11, 2014, 08:00 ET

Immune's CEO To Present on Personalized Medicine at the 2014 NY/ NJ CEO Biotech Conference

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced that Dr. Daniel Teper, Chairman & CEO, will discuss personalized medicine at a panel...

Oct 22, 2014, 02:30 ET

New Clinical Data Supports Development Of Bertilimumab In Both Ulcerative Colitis And Crohn's Disease

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company") announces that Dr. Tomer Adar, a gastro-enterologist at the Institute...

Sep 18, 2014, 02:30 ET

Immune Pharmaceuticals Initiates Phase II Clinical Trial In Ulcerative Colitis

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company") announces today that it has initiated the screening of patients for a...

Sep 08, 2014, 07:00 ET

Immune Pharmaceuticals Presenting At The 16th Annual Rodman & Renshaw Global Investment Conference, September 10, 2014

 Immune Pharmaceuticals Inc. (NASDAQ and NASDAQ OMX First North Premier, Stockholm: "IMNP"; "Immune" or "the Company"), today announced it will...

Aug 19, 2014, 02:30 ET

Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market

Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP"), a biotechnology company, today announced that it has...

Aug 14, 2014, 02:30 ET

Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials

 Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP"), announced today its operating results for the...

Jul 30, 2014, 02:30 ET

Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin

 Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP."; "Immune" or "the Company") announces today that it...

Jul 24, 2014, 02:30 ET

Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin

Lyfebulb, the International Pemphigus Pemphigoid Foundation (IPPF) and Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier,...

Nov 26, 2013, 00:01 ET

Immune Pharmaceuticals' Common Stock Approved for Trading on NASDAQ OMX First North Premier

 Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that its common stock has been approved for...

Nov 20, 2013, 00:01 ET

Immune Pharmaceuticals Reports Third Quarter 2013 Financial Results

 Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) ("Immune" or the "Company") announced today its financial results...

Nov 01, 2013, 00:01 ET

Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange

 Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that it has appointed Erik Penser Bankaktiebolag...

Oct 16, 2013, 00:01 ET

New Data Supports Clinical Rationale for Bertilimumab in Ulcerative Colitis

 Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that Tomer Adar, M.D. at the Digestive Diseases...

Oct 15, 2013, 00:01 ET

Immune Pharmaceuticals Announces Changes to its Board of Directors

Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP), announced today that Rene Lerer, M.D., Executive Chairman of Magellan...

Oct 03, 2013, 00:01 ET

IMMUNE Pharmaceuticals Inc. to Present at 12th Annual BIO Investor Forum

 Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that Dr. Daniel G. Teper, Company Chairman and...

Sep 30, 2013, 00:01 ET

Immune Pharmaceuticals Announces Focus on Capital Raising and Primary Listing in The United States

 Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange and OTCQX: IMNP) ("IMMUNE" or the "Company") announced today that following the...

Sep 23, 2013, 00:01 ET

Immune Pharmaceuticals Inc. Trading Symbol is Now IMNP on Both NASDAQ OMX Stockholm Exchange and OTCQX Trading Platform

 Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: IMNP, formerly EPCTD) announced today that effective September 23,...